191 related articles for article (PubMed ID: 35633653)
1. A study on predicting cases that would benefit from proton beam therapy in primary liver tumors of less than or equal to 5 cm based on the estimated incidence of hepatic toxicity.
Uchinami Y; Katoh N; Suzuki R; Kanehira T; Tamura M; Takao S; Matsuura T; Miyamoto N; Fujita Y; Koizumi F; Taguchi H; Yasuda K; Nishioka K; Yokota I; Kobashi K; Aoyama H
Clin Transl Radiat Oncol; 2022 Jul; 35():70-75. PubMed ID: 35633653
[TBL] [Abstract][Full Text] [Related]
2. Study of hepatic toxicity in small liver tumors after photon or proton therapy based on factors predicting the benefits of proton.
Uchinami Y; Katoh N; Abo D; Morita R; Taguchi H; Fujita Y; Kanehira T; Suzuki R; Miyamoto N; Takao S; Matsuura T; Sho T; Ogawa K; Orimo T; Kakisaka T; Kobashi K; Aoyama H
Br J Radiol; 2023 Mar; 96(1144):20220720. PubMed ID: 36633335
[TBL] [Abstract][Full Text] [Related]
3. A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer.
Rwigema JM; Langendijk JA; Paul van der Laan H; Lukens JN; Swisher-McClure SD; Lin A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):553-562. PubMed ID: 30625409
[TBL] [Abstract][Full Text] [Related]
4. Normal Tissue Complication Probability Modelling for Toxicity Prediction and Patient Selection in Proton Beam Therapy to the Central Nervous System: A Literature Review.
Gaito S; Burnet N; Aznar M; Crellin A; Indelicato DJ; Ingram S; Pan S; Price G; Hwang E; France A; Smith E; Whitfield G
Clin Oncol (R Coll Radiol); 2022 Jun; 34(6):e225-e237. PubMed ID: 35042622
[TBL] [Abstract][Full Text] [Related]
5. Identification of patient benefit from proton beam therapy in brain tumour patients based on dosimetric and NTCP analyses.
Dutz A; Lühr A; Troost EGC; Agolli L; Bütof R; Valentini C; Baumann M; Vermeren X; Geismar D; Timmermann B; Krause M; Löck S
Radiother Oncol; 2021 Jul; 160():69-77. PubMed ID: 33872640
[TBL] [Abstract][Full Text] [Related]
6. Comparison of intensity modulated proton therapy beam configurations for treating thoracic esophageal cancer.
Oonsiri S; Kitpanit S; Kannarunimit D; Chakkabat C; Lertbutsayanukul C; Prayongrat A
Phys Imaging Radiat Oncol; 2022 Apr; 22():51-56. PubMed ID: 35514527
[TBL] [Abstract][Full Text] [Related]
7. Dose-Volume and Radiobiological Model-Based Comparative Evaluation of the Gastrointestinal Toxicity Risk of Photon and Proton Irradiation Plans in Localized Pancreatic Cancer Without Distant Metastasis.
Raturi VP; Tochinai T; Hojo H; Rachi T; Hotta K; Nakamura N; Zenda S; Motegi A; Ariji T; Hirano Y; Baba H; Ohyoshi H; Nakamura M; Okumura M; Bei Y; Akimoto T
Front Oncol; 2020; 10():517061. PubMed ID: 33194580
[No Abstract] [Full Text] [Related]
8. Estimation of the risk for radiation-induced liver disease following photon- or proton-beam radiosurgery of liver metastases.
Mondlane G; Ureba A; Gubanski M; Lind PA; Siegbahn A
Radiat Oncol; 2018 Oct; 13(1):206. PubMed ID: 30348194
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Estimated Late Toxicities between IMPT and IMRT Based on Multivariable NTCP Models for High-Risk Prostate Cancers Treated with Pelvic Nodal Radiation.
Chilukuri S; Sundar S; Patro K; Sawant M; Sivaraman R; Arjunan M; Panda PK; Sharma D; Jalali R
Int J Part Ther; 2022; 9(1):42-53. PubMed ID: 35774485
[TBL] [Abstract][Full Text] [Related]
10. Volumetric-modulated arc therapy vs. c-IMRT in esophageal cancer: a treatment planning comparison.
Yin L; Wu H; Gong J; Geng JH; Jiang F; Shi AH; Yu R; Li YH; Han SK; Xu B; Zhu GY
World J Gastroenterol; 2012 Oct; 18(37):5266-75. PubMed ID: 23066322
[TBL] [Abstract][Full Text] [Related]
11. A Patient Selection Approach Based on NTCP Models and DVH Parameters for Definitive Proton Therapy in Locally Advanced Sinonasal Cancer Patients.
Mirandola A; Russo S; Bonora M; Vischioni B; Camarda AM; Ingargiola R; Molinelli S; Ronchi S; Rossi E; Vai A; Iacovelli NA; Thariat J; Ciocca M; Orlandi E
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681661
[TBL] [Abstract][Full Text] [Related]
12. A treatment planning study of proton arc therapy for para-aortic lymph node tumors: dosimetric evaluation of conventional proton therapy, proton arc therapy, and intensity modulated radiotherapy.
Rah JE; Kim GY; Oh DH; Kim TH; Kim JW; Kim DY; Park SY; Shin D
Radiat Oncol; 2016 Oct; 11(1):140. PubMed ID: 27769262
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Radiation-Induced Liver Disease in Eastern and Western Patients With Hepatocellular Carcinoma Undergoing Proton Beam Therapy.
Hsieh CE; Venkatesulu BP; Lee CH; Hung SP; Wong PF; Aithala SP; Kim BK; Rao A; Tung-Chieh Chang J; Tsang NM; Wang CC; Lee CC; Lin CC; Tseng JH; Chou WC; Wang YC; Krishnan S; Hong JH
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):73-86. PubMed ID: 30797890
[TBL] [Abstract][Full Text] [Related]
14. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
[TBL] [Abstract][Full Text] [Related]
15. Investigate the Dosimetric and Potential Clinical Benefits Utilizing Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost Technique for Locally Advanced Pancreatic Cancer: A Comparison Between Photon and Proton Beam Therapy.
Liu P; Gao XS; Wang Z; Li X; Xi C; Jia C; Xie M; Lyu F; Ding X
Front Oncol; 2021; 11():747532. PubMed ID: 34631584
[TBL] [Abstract][Full Text] [Related]
16. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication.
Cheng JC; Wu JK; Huang CM; Liu HS; Huang DY; Cheng SH; Tsai SY; Jian JJ; Lin YM; Cheng TI; Horng CF; Huang AT
Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):156-62. PubMed ID: 12182986
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a mixed beam therapy for postmastectomy breast cancer patients: Bolus electron conformal therapy combined with intensity modulated photon radiotherapy and volumetric modulated photon arc therapy.
Zhang R; Heins D; Sanders M; Guo B; Hogstrom K
Med Phys; 2018 Jul; 45(7):2912-2924. PubMed ID: 29749075
[TBL] [Abstract][Full Text] [Related]
18. Assessing the uncertainty in a normal tissue complication probability difference (∆NTCP): radiation-induced liver disease (RILD) in liver tumour patients treated with proton vs X-ray therapy.
Kobashi K; Prayongrat A; Kimoto T; Toramatsu C; Dekura Y; Katoh N; Shimizu S; Ito YM; Shirato H
J Radiat Res; 2018 Mar; 59(suppl_1):i50-i57. PubMed ID: 29538699
[TBL] [Abstract][Full Text] [Related]
19. Benefit of using biologic parameters (EUD and NTCP) in IMRT optimization for treatment of intrahepatic tumors.
Thomas E; Chapet O; Kessler ML; Lawrence TS; Ten Haken RK
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):571-8. PubMed ID: 15890602
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a Hybrid IMRT/VMAT technique with non-coplanar VMAT and non-coplanar IMRT for unresectable olfactory neuroblastoma using the RayStation treatment planning system-EUD, NTCP and planning study.
Raturi VP; Motegi A; Zenda S; Nakamura N; Hojo H; Kageyama SI; Okumura M; Rachi T; Ohyoshi H; Tachibana H; Motegi K; Ariji T; Nakamura M; Hirano Y; Hirata H; Akimoto T
J Radiat Res; 2021 May; 62(3):540-548. PubMed ID: 33839761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
